Strausz J, Müller-Quernheim J, Ferlinz R
Abteilung Innere Medizin mit Schwerpunkt Pneumologie, Universität Mainz.
Dtsch Med Wochenschr. 1989 May 12;114(19):744-9. doi: 10.1055/s-2008-1066666.
Serum sIL-2-R levels were measured in 28 sarcoidosis patients at multiple time points before, during, and after therapy, with a mean follow-up time of 10.2 +/- 5.2 months, and the results compared with the clinical activity of the disease. Before therapy, 20 out of 24 episodes with active disease exhibited elevated levels of sIL-2-R (918 +/- 362 U/ml). In inactive disease after tapering off corticoid therapy the sIL-2-R levels were 453 +/- 274 U/ml. Disease activity under therapy also correlated with sIL-2-R serum levels. 23 out of 29 episodes with signs of activity under therapy had elevated sIL-2-R levels (808 +/- 409 U/ml). Only three of 28 patients in whom disease activity ceased after therapy had been initiated had raised sIL-2-R levels (mean: 401 +/- 140 U/ml). These results demonstrate that the activity of pulmonary sarcoidosis is reflected accurately by the serum levels of sIL-2-R, suggesting that the course of the disease can be monitored by this approach.
在28例结节病患者治疗前、治疗期间和治疗后的多个时间点测量血清可溶性白细胞介素-2受体（sIL-2-R）水平，平均随访时间为10.2±5.2个月，并将结果与疾病的临床活动情况进行比较。治疗前，24例活动期疾病发作中有20例sIL-2-R水平升高（918±362 U/ml）。在逐渐减少皮质类固醇治疗后的非活动期疾病中，sIL-2-R水平为453±274 U/ml。治疗期间的疾病活动也与sIL-2-R血清水平相关。29例治疗期间有活动迹象的发作中有23例sIL-2-R水平升高（808±409 U/ml）。在开始治疗后疾病活动停止的28例患者中，只有3例sIL-2-R水平升高（平均：401±140 U/ml）。这些结果表明，血清sIL-2-R水平可准确反映肺结节病的活动情况，提示可通过这种方法监测疾病进程。
